Drugs / Alclometasone dipropionate
last change Nov 2006 re-read 3 minutes ago

Alclometasone dipropionate

Small molecule targets NR3C1 via activation

Developed for
psoriasis
Investigated by
GlaxoSmithKline

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) ACLOVATE — 1996-04-26 fda.gov ↗
Approved US (FDA) ACLOVATE — 1982-12-14 fda.gov ↗

Trials 1

today
US approved 1982
NCT02075632 · Ph 2
19821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02075632 Sep → Nov 2006 allergic disease, psoriasis GlaxoSmithKline Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Alclometasone dipropionate ClinicalTrials.gov intervention name — accepted as the source's own label NCT02075632 ↗
Known as Aclovate ChEMBL registry synonym — accepted as the source's own label CHEMBL1200989 ↗
Known as Alclometasona ChEMBL registry synonym — accepted as the source's own label CHEMBL1200989 ↗
Known as Alclometasone 17,21-dipropionate ChEMBL registry synonym — accepted as the source's own label CHEMBL1200989 ↗
Known as Modrasone ChEMBL registry synonym — accepted as the source's own label CHEMBL1200989 ↗
Known as NSC-758914 ChEMBL registry synonym — accepted as the source's own label CHEMBL1200989 ↗
Known as SCH 22219 ChEMBL registry synonym — accepted as the source's own label CHEMBL1200989 ↗
Action Activate “Glucocorticoid receptor agonist” CHEMBL1200989 ↗
Modality Small molecule — CHEMBL1200989 ↗
Route Topical “will be applied by the participants topically on the affected areas” NCT02075632 ↗
Target NR3C1 “Glucocorticoid receptor agonist” CHEMBL1200989 ↗